# Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

> **NCT00539240** · PHASE2,PHASE3 · COMPLETED · sponsor: **US Department of Veterans Affairs** · enrollment: 236 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Rabeprazole 20mg, placebo dinner and bedtime
- **DRUG:** Rabeprazole 20 mg two times, Placebo at bedtime
- **DRUG:** Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant

## Key facts

- **NCT ID:** NCT00539240
- **Lead sponsor:** US Department of Veterans Affairs
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-04
- **Final completion:** 2011-11
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2014-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539240, "Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00539240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*